The last decade has produced a transformative expansion in biologic therapy options for patients with moderate-to-severe psoriasis and atopic dermatitis. IL-17 inhibitors, IL-23 inhibitors, IL-4/13 inhibitors, and JAK inhibitors are now standard of care for patients who fail conventional therapies — and the National Psoriasis Foundation (NPF) estimates that more than 1.5 million patients in the United States are currently on biologic therapy for psoriatic disease alone, with atopic dermatitis biologics representing another rapidly growing population.
These medications are extraordinarily effective. Dupilumab achieves clear or almost-clear skin in over 70% of atopic dermatitis patients in clinical trials. Risankizumab and guselkumab achieve similar results for plaque psoriasis. But every one of these medications requires a prior authorization before the insurer will pay — and most require step therapy, annual renewals, and detailed clinical documentation that together generate an administrative burden that specialty practices without structured systems simply cannot absorb.
A psoriasis and eczema specialty VA is built specifically for this administrative environment.
Biologic Prior Authorization: The Core Workflow
Biologic prior authorizations in dermatology are among the most complex in outpatient medicine. Each insurer has its own step therapy requirements — typically requiring documented failure of two or more conventional therapies (methotrexate, cyclosporine, phototherapy, or specific topicals) before approving a biologic. The documentation of those failures must match the insurer's specific criteria, which vary by formulary and can change annually.
A specialty dermatology VA manages the PA workflow end-to-end:
- PA initiation — submitting prior authorization requests through the insurer's portal, phone line, or fax system, with the correct clinical documentation package attached
- Step therapy documentation — pulling evidence of prior therapy failures from the chart and formatting them to match insurer-specific requirements
- Status tracking — monitoring every open PA request in a tracking system, following up at 72-hour intervals, and escalating delays to the clinical team
- Denial management — when a PA is denied, preparing the clinical summary for peer-to-peer review between the physician and the insurer's medical director, scheduling the peer-to-peer call, and tracking its outcome
- Annual renewal management — proactively initiating renewals 60–90 days before existing authorizations expire to prevent coverage gaps
The NPF reports that 57% of dermatology biologic prescriptions face at least one prior authorization challenge before approval, and that the average approval process takes 11 days with the risk of multi-week delays on denial and appeal. A VA who owns this pipeline systematically reduces delays and approval failures.
Patient Assistance Program Enrollment
Biologic medications for psoriasis and atopic dermatitis are expensive — list prices range from $20,000 to $40,000 annually before insurance. For uninsured or underinsured patients, and for those who face prohibitive copays even with coverage, manufacturer patient assistance programs (PAPs) and copay cards are the pathway to treatment access.
Every major biologic manufacturer — AbbVie (Skyrizi), Eli Lilly (Taltz), Sanofi/Regeneron (Dupixent), Pfizer (Cibinqo), UCB (Bimzelx) — offers both a patient assistance program for qualifying uninsured patients and a copay assistance card for commercially insured patients. Enrolling patients in these programs requires gathering income documentation, completing manufacturer-specific application forms, and tracking enrollment status and annual renewal requirements.
A dermatology VA manages PAP enrollment:
- Identifying patients who are candidates for assistance at the time of biologic prescription
- Completing and submitting manufacturer applications with the required documentation
- Tracking enrollment status and communicating approval to the patient and pharmacy
- Managing annual re-enrollment and documenting income changes that affect eligibility
Practices that systematically enroll eligible patients in PAPs see significantly higher biologic treatment initiation rates — fewer patients abandon their prescription due to cost shock.
Between-Visit Patient Support
Chronic disease patients — particularly those starting a new biologic — need active support between appointments. Common concerns include injection technique, injection site reactions, managing the initial weeks before therapeutic response, and knowing when to call the office. Without proactive support, patients escalate to calls, portal messages, and unnecessary appointments that consume clinical staff time.
A specialty dermatology VA manages a structured between-visit communication protocol:
- Post-injection training follow-up — checking in within one week of the first self-administered injection to confirm technique and address concerns
- 4-week efficacy check-in — assessing early treatment response using validated tools (DLQI for quality of life, BSA for disease extent) via a structured questionnaire
- Adherence monitoring — tracking refill timing through pharmacy data or patient-reported information, identifying patients who are delaying refills
- Side effect screening — using physician-approved screening questions to identify early signs of concerning side effects (conjunctivitis for dupilumab, inflammatory bowel disease for IL-17 inhibitors) for clinical escalation
The NPF's patient survey data shows that psoriasis patients who receive structured between-visit support report significantly higher treatment adherence and quality of life scores at 12 months compared to those managed with standard care.
Building the Chronic Disease Administrative Infrastructure
Psoriasis and eczema specialty practices that treat the sickest patients have the highest administrative complexity. The practices that serve these patients most effectively are those with systematic biologic management infrastructure — PA pipelines that don't miss deadlines, PAP enrollments that don't leave patients without access, and follow-up protocols that catch problems before they become crises.
For specialty dermatology practices ready to build that infrastructure, Stealth Agents provides trained medical administrative VAs deployable into biologic management workflows within weeks.
Sources
- National Psoriasis Foundation (NPF) — Biologic Treatment Landscape and Access Report, 2024
- NPF — Prior Authorization Challenges in Dermatology Survey, 2024
- Journal of the American Academy of Dermatology — Dupilumab Clinical Efficacy in Atopic Dermatitis: 52-Week Data, 2023